Brief: Astellas Pharma Inc - Astellas Confirms Phase 2 Gleam Trial Did Not Meet Primary Endpoint Of Overall Survival In Patients With Metastatic Pancreatic Cance
14/10/2025 24:31
Oct 14 (Reuters) - Astellas Pharma Inc 4503.T: ASTELLAS PHARMA INC: ASTELLAS CONFIRMS PHASE 2 GLEAM TRIAL DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH METASTATIC PANCREATIC CANCE ASTELLAS PHARMA INC: IMPACT OF THIS RESULT ON ASTELLAS' FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2026, IS EXPECTED TO BE MINOR Source text: ID:nTSvm8bbb7 Further company coverage: 4503.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn